Daily Archives: October 30, 2020
Report: COVID-19 infection fatality ratio estimates from seroprevalence
30 Oct, 2020 | 01:16h | UTCFull report: COVID-19 Infection Fatality Ratio: Estimates from Seroprevalence
Commentary on Twitter
UPDATE #COVID19 Infection Fatality Ratio (IFR):
➡️1.15% IFR (high income countries)
➡️0.23% IFR (low income countries)
➡️0.1% IFR (under 40 year olds)
➡️5.6% IFR (over 80 year olds)
➡️Risk of COVID19 death doubles every eight years of age?Report 34 https://t.co/171hx5LMvp pic.twitter.com/M1rmq673Rf
— MRC Centre for Global Infectious Disease Analysis (@MRC_Outbreak) October 29, 2020
CDC Report: 1 infected camper likely led to 115 coronavirus cases at an overnight camp
30 Oct, 2020 | 01:15h | UTCOriginal report: COVID-19 Outbreak at an Overnight Summer School Retreat ― Wisconsin, July–August 2020 – CDC Morbidity and Mortality Weekly Report
Commentary on Twitter
When 1 high school student who tested covid negative 1 week prior to a retreat led to 116 cases (76% of the students and staff)https://t.co/vjKImeE4vg @CDCgov
— Eric Topol (@EricTopol) October 29, 2020
Perspective: Will SARS-CoV-2 become endemic?
30 Oct, 2020 | 01:12h | UTCWill SARS-CoV-2 become endemic? – Science
It may be time to reset expectations on when we’ll get a Covid-19 vaccine
30 Oct, 2020 | 01:10h | UTCIt may be time to reset expectations on when we’ll get a Covid-19 vaccine – STAT
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
30 Oct, 2020 | 01:14h | UTCThe ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug – Science
Commentaries on Twitter
Remdesivir, despite failing in Solidarity trial, received FDA approval without input from outside advisory group. EU cut pricing deal with Gilead without knowing Solidarity data. @kakape and I explain in "The ‘very, very bad look’ of remdesivir" https://t.co/yTKq2A1WQT pic.twitter.com/NhBLum09VG
— Jon Cohen (@sciencecohen) October 28, 2020
Uncovering a scandal about Gilead and Remdesivir
Deep reporting by @sciencecohen and @kakape @ScienceMagazine
The company knew the #SOLIDARITY trial data well before it its preprint. And so did the FDA before giving a full approval, w/o external review https://t.co/4REMEwTvc5— Eric Topol (@EricTopol) October 28, 2020
Perspective: Why schools probably aren’t COVID hotspots
30 Oct, 2020 | 01:11h | UTCWhy schools probably aren’t COVID hotspots – Nature
Opinion: For now, it’s unethical to use human challenge studies for SARS-CoV-2 vaccine development
30 Oct, 2020 | 01:09h | UTC
A room, a bar and a classroom: how the coronavirus is spread through the air
30 Oct, 2020 | 01:08h | UTCA room, a bar and a classroom: how the coronavirus is spread through the air – El Pais
Commentary on Twitter (thread – click for more)
I have spent the past day weighing whether to like article because it is a fantastically executed example of #scicomm or dislike it because it is propaganda that distorts the evidence.https://t.co/5svH2JJ8gZ via @elpaisinenglish
— Andrew Morris (@ASPphysician) October 29, 2020
Videos in clinical medicine: Percutaneous Tracheostomy
30 Oct, 2020 | 01:05h | UTCPercutaneous Tracheostomy – New England Journal of Medicine
AHA Scientific Statement: Prevention of complications in the cardiac intensive care unit
30 Oct, 2020 | 01:06h | UTCCommentary: New strategies suggested for critical heart care in the ICU – American Heart Association
Non-surgical management of knee osteoarthritis: Comparison of ESCEO and OARSI 2019 guidelines
30 Oct, 2020 | 01:02h | UTCCommentary: Knee OA guidance for clinicians simplified and streamlined – University of Oxford
Study provides new estimates of breast cancer risks associated with different hormone replacement therapy preparations
30 Oct, 2020 | 01:04h | UTCCommentaries: Study provides new estimates of breast cancer risks associated with HRT – University of Oxford AND New estimates of breast cancer risks associated with HRT – The BMJ AND HRT: Breast Ca Risk Tied to Hormone Type, Duration of Tx – Physician’s Weekly
KDIGO Controversies Conference on onco-nephrology
30 Oct, 2020 | 01:03h | UTC
Commentary on Twitter
.@goKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer ca. 2020 from @Kidney_Int #Nephpearls#Onconephrology ?
?? https://t.co/u6ANtXdKfy pic.twitter.com/4xJ0gGohoE— Edgar V. Lerma ?? (@edgarvlermamd) October 28, 2020